Please login to the form below

Not currently logged in
Email:
Password:

Cerezyme

This page shows the latest Cerezyme news and features for those working in and with pharma, biotech and healthcare.

Sanofi rare disease drug a breakthrough, says FDA

Sanofi rare disease drug a breakthrough, says FDA

Genzyme has built the core of its business by focusing on this group, developing big-selling brands such as Gaucher therapy Cerezyme (imiglucerase alfa), Fabrazyme (agalsidase beta) for Fabry disease and

Latest news

  • Genzyme's oral Gaucher drug cleared in Europe Genzyme's oral Gaucher drug cleared in Europe

    Patients with Gaucher disease are currently started on injectable therapy with enzyme replacement drugs such as Genzyme's own Cerezyme (imiglucerase), the top-selling medicine for the rare disease with sales ... Analysts have suggested Cerdelga could

  • Orphan drugs in latest CHMP recommendations Orphan drugs in latest CHMP recommendations

    be treated with intravenous injections such as enzyme replacement treatment Cerezyme (imiglucerase), also made by Genzyme. ... Cerdelga has demonstrated it is as effective as Cerezyme in clinical trials and was approved in the US in August.

  • FDA gives green light to Genzyme’s oral Gaucher drug FDA gives green light to Genzyme’s oral Gaucher drug

    FDA gives green light to Genzyme’ s oral Gaucher drug. Oral therapy Cerdelga is set to complement intravenous Cerezyme. ... the possibility that Cerdelga could be used alongside Cerezyme as a combination regimen.

  • EMA publishes European drug shortage details EMA publishes European drug shortage details

    EMA publishes European drug shortage details. First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... Drugs featured in the first version of the shortages catalogue include Sanofi/Genzyme's Cerezyme (imiglucerase) and

  • Sanofi predicts return to growth in second half Sanofi predicts return to growth in second half

    Genzyme's portfolio of rare disease therapies increased more than a quarter to 493m as restricted supplies of Gaucher disease therapy Cerezyme (imiglucerase) and Fabrazyme (agalsidase beta) for Fabry disease caused ... Cerezyme grew 17 per cent to 171m,

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics